Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.
Cardiovasc Diabetol
; 20(1): 75, 2021 03 31.
Article
in English
| MEDLINE | ID: covidwho-1166910
ABSTRACT
The 6th Cardiovascular Outcome Trial (CVOT) Summit "Cardiovascular and Renal Outcomes 2020" was the first to be held virtually on October 29-30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA-CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed.The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18-19, 2021 ( http//www.cvot.org ).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Clinical Trials as Topic
/
Congresses as Topic
/
Renal Insufficiency, Chronic
/
Research Report
/
COVID-19
Type of study:
Observational study
/
Prognostic study
/
Qualitative research
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Cardiovasc Diabetol
Journal subject:
Vascular Diseases
/
Cardiology
/
Endocrinology
Year:
2021
Document Type:
Article
Affiliation country:
S12933-021-01254-1
Similar
MEDLINE
...
LILACS
LIS